Lv53
970 积分 2022-08-02 加入
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
4个月前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
5个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
6个月前
已完结
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma
8个月前
已完结
Recent Advances in the Treatment of Melanoma
8个月前
已完结
Cell atlas of the human ocular anterior segment: Tissue-specific and shared cell types
8个月前
已完结
Mitigation and management strategies for ocular events associated with tisotumab vedotin
8个月前
已完结
Mitigation and management strategies for ocular events associated with tisotumab vedotin
8个月前
已关闭
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
8个月前
已完结
皖公网安备34019202002308
